AHA comments on the Drug Enforcement Administration’s (DEA) notice of proposed rulemaking on aggregate production quotas for Schedule I and II controlled substances.
Letters
Throughout the year, the AHA comments on a vast number of proposed and interim final rules put forth by the federal regulatory agencies. In addition, AHA communicates with federal legislators to convey the hospital field's position on potential legislative changes that would impact patients and patient care. Below are the most recent letters from the AHA to these bodies.
Latest
Aug 23, 2018
AHA letter to the US Senate supporting Amendment #3787 to address ‘out-of-control cost’ of prescription drugs.
Aug 3, 2018
RE: CMS-1720-NC, Request for Information Regarding the Physician Self-referral Law
Jul 30, 2018
AHA shares Value-Based Care recommendations with Congressional Caucus.
Jul 27, 2018
AHA comments on the Centers for Medicare & Medicaid Services' agency information collection notice on the home health “Review Choice” demonstration.
Jul 20, 2018
AHA letter to the Senate expressing support for Robert Wilkie Department.of Veteran Affairs Nomination.
Jul 17, 2018
AHA expresses disappointment that the Agency for Healthcare Research and Quality is shutting down the National Guidelines Clearinghouse.
Jul 17, 2018
AHA, health organizations letter to CMS regarding its decision to suspend billions of dollars in annual payments to insurers as required under the Affordable Care Act’s risk-adjustment program.
Jul 16, 2018
AHA comments on the 340B section of the Department of Health and Human Services’ Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Jul 16, 2018
AHA comments on the Department of Health and Human Services’ Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.